Evidence map›Paper›PMID 41659384›Full record

ArticleInternational journal of pharmaceutics: X2026

A prostate-specific membrane antigen targeted small molecule-drug conjugate for efficient prostate cancer therapy at a low dosage.

Jingjing Zhang, Fanchun Hu, Caiting Deng, Yuhan Ding, Yuchen Yang, Shupeng Han, Jun Liu, Feifei An, Mingsong Shi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jingjing ZhangSchool of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Fanchun HuSchool of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Caiting DengSchool of Basic Medical Science, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Yuhan DingSchool of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Yuchen YangSchool of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Shupeng HanDepartment of Breast Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Jun LiuMedical Imaging Key Laboratory of Sichuan Province and School of Pharmacy, North Sichuan Medical College, Nanchong 637000, China.
Feifei AnSchool of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Mingsong ShiNational Health Commission Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621099, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA), which is overexpressed in most prostate cancer cells, serves as an ideal target for precision therapy. The clinical utility of the potent chemotherapeutic agent SN38 is hindered by its poor water solubility and systemic toxicity. Herein, we present a novel, fully water-soluble small-molecule drug conjugate (SMDC), SN38-SS-3PEG

Indexed as

PEGProstate cancerPSMASMDCSN38

Identifiers

PMID41659384
PMCPMC12874589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.